New target-based agents involve new clinical trial designs.

Area of Science:

• Oncology
• Clinical Pharmacology
• Cancer Research

Background:

• Clinical cancer investigation relies on clinical trials to evaluate new therapeutic agents.
• The development and efficacy measurement of novel target-based cancer drugs differ significantly from traditional cytotoxic chemotherapy.
• Target-based agents aim to inhibit cancer cell proliferation rather than cause direct tumor shrinkage.

Purpose of the Study:

• To outline the distinct endpoints and methodologies employed in different phases of clinical cancer trials for target-based agents.
• To highlight the importance of oncopharmacogenomic studies in assessing target inhibition.
• To differentiate the evaluation criteria between phase I, II, and III clinical trials.

Main Methods:

• Phase I trials: Determine optimal biological response and minimal toxicity, incorporating oncopharmacogenomic analysis of tumor biopsies for target inhibition assessment.
• Phase II studies: Evaluate time to progression and biological activity as key endpoints.
• Phase III trials: Focus on determining overall survival as the primary outcome.

Main Results:

• Phase I trials establish safety and biological activity, guiding dose selection.
• Phase II trials provide preliminary efficacy data based on progression and biological markers.
• Phase III trials confirm the clinical benefit and survival advantage of the new agents.

Conclusions:

• Clinical trial design must be adapted for target-based cancer agents, with distinct endpoints for each phase.
• Oncopharmacogenomics is crucial for validating target engagement in early-phase trials.
• Sequential evaluation through phase I, II, and III trials is essential for establishing the efficacy and survival benefit of novel cancer therapies.